|
Originally published In Press as doi:10.1074/jbc.M005186200 on July 27, 2000
J. Biol. Chem., Vol. 275, Issue 41, 32200-32207, October 13, 2000
Folding and Maturation of Tyrosinase-related Protein-1 Are
Regulated by the Post-translational Formation of Disulfide Bonds
and by N-Glycan Processing*
Gabriela
Negroiu ,
Raymond A.
Dwek§, and
Stefana M.
Petrescu ¶
From the Institute of Biochemistry of the Romanian
Academy, Splaiul Independentei 296, 77700 Bucharest, Romania and
the § Oxford Glycobiology Institute, Department of
Biochemistry, University of Oxford, South Parks Road,
Oxford OX1 3QU, United Kingdom
Received for publication, June 15, 2000, and in revised form, July 25, 2000
 |
ABSTRACT |
In this study we have explored the endoplasmic
reticulum associated events accompanying the maturation of the
tyrosinase-related protein-1 (TRP-1) nascent chain synthesized in mouse
melanoma cells. We show that TRP-1 folding process occurs much more
rapidly than for tyrosinase, a highly homologous protein, being
completed post-translationally by the formation of critical disulfide
bonds. In cells pretreated with dithiothreitol (DTT), unfolded TRP-1 is
retained in the endoplasmic reticulum by a prolonged interaction with calnexin and BiP before being targeted for degradation. The TRP-1 chain was able to fold into DTT-resistant conformations both in
the presence or absence of -glucosidase inhibitors, but folding
occurred through different pathways. During the normal folding pathway,
TRP-1 interacts with calnexin. In the presence of -glucosidase
inhibitors, the interaction with calnexin is prevented, with TRP-1
folding being assisted by BiP. In this case, the process has
similar kinetics to that of untreated TRP-1 and yields a compact form
insensitive to DTT as well. However, this form has different thermal
denaturation properties than the native conformation. We conclude that
disulfide bridge burring is crucial for the TRP-1 export. This suggests
that although various folding pathways may complete this process, the
native form may be acquired only through the normal unperturbed pathway.
 |
INTRODUCTION |
Tyrosinase-related proteins
(TRPs)1 include tyrosinase,
TRP-1, and TRP-2. They constitute a family of membrane proteins
structurally related but with distinct enzymatic functions along the
biosynthetic pathway of melanin pigment in animal tissues (1). TRP-1 or glycoprotein 75 is the most abundant glycoprotein in melanocytes (2, 3)
and one of the best characterized melanoma antigens (4, 5). It is well
known that TRP-1 has an important role in the maturation and stability
of melanosomes, site organelles of the melanin synthesis and deposition
(5, 6). TRP-1 maps to the brown locus on chromosome 4 (7,
8). Unlike mutations at albino locus on chromosome 7 that
encodes the tyrosinase, mutations at brown locus do not
eliminate pigmentation but result in synthesis of brown instead of
black eumelanin (9). Within the multimeric complex formed by TRP
enzymes in melanosomal membrane (10), TRP-1 plays an important role in
stabilization of tyrosinase, thus indirectly controlling the melanin
production (11).
TRP-1 is a type I membrane glycoprotein with 533 amino acids, 6 potential N-glycosylation sites, 17 cysteine residues
grouped in two cysteine-rich domains, and two copper binding domains
(1, 12, 13). TRP-1 and tyrosinase share a significant level of homology
in several regions including the cysteine-rich domains and the
potential N-glycosylation sites (1).
TRP-1 from both human (5) and mouse melanoma (14) follows the regular
biosynthesis pathway as most of the membrane glycoproteins. After
synthesis in the ER compartment, the partially
N-glycosylated polypeptide transits the Golgi compartment,
and it is finally transported to its target organelle, the melanosome.
The nascent polypeptide of a membrane glycoprotein is translocated into
the ER compartment and folds into the native conformation assisted by
molecular chaperones and other ER-resident molecules. The polypeptide compaction is associated for most of them with the formation of disulfide bonds (oxidative folding) that stabilize the native conformation. The reversible formation of disulfides is facilitated by
the oxidizing environment of the ER lumen and is catalyzed by specific
enzymes (15-17). In order to assess the role of disulfide formation on
polypeptide intracellular transport, sorting, and processing, the ER
redox potential can be manipulated by culturing the cells in the
presence of reducing agents (18-22).
N-Glycan processing has been shown to be an important event
involved in the folding of the nascent chain.
N-Glycosylation sites are occupied in the ER compartment by
the co-translational attachment of the core glycan,
Glc3Man9GlcNAc2. The trimming of Glc3Man9GlcNAc2 precursor by ER
glucosidases I and II initiates the N-glycan processing and
interferes with the folding events. The resulting monoglucosylated
form, GlcMan9GlcNAc2, becomes substrate for the
lectin chaperones calnexin and calreticulin that assist the polypeptide
until the native conformation is achieved (23). In the presence of
-glucosidase I inhibitors, such as deoxynojirimicin, N-butyl-deoxynojirimicin (NB-DNJ), and castanospermine, the
trimming of the first glucose is abolished. Thus, the glucosylated
N-glycans cannot be further processed, and glycoprotein
folding cannot be controlled by the calnexin cycle. Calnexin and
calreticulin have been shown to direct the bound polypeptide chain into
deglucosylation/reglucosylation cycles in which the lectins act in
conjunction with glucosyltransferase and -glucosidase II to retain
the nascent chain in repeated binding and release cycles until complete
folding (24). The components of the calnexin cycle are elements of the
ER quality control system, which eliminates the grossly misfolded
proteins and allows the export of the correctly folded ones. It has
been reported that another component of the quality control is the
chaperone BiP, the immunoglobulin heavy chain binding protein. BiP is a
molecular chaperone that transiently interacts with unfolded stretches
of a nascent polypeptide as long as these regions have not reached their folded conformation (25). Some proteins remain bound to BiP until
they are degraded, and a role for BiP as a lid of the translocon pore
has been recently suggested (26). Although sequential interactions of
the chain with the two chaperones and complexes between calnexin and
BiP have been reported, it is still unclear if BiP and calnexin are
required for the correct folding of any individual glycoprotein
(27).
We have previously shown that inhibition of early N-glycan
processing with NB-DNJ resulted in tyrosinase inactivation and a
dramatic loss of cell pigmentation in melanoma cells (28). It has been
also shown that the inhibitory effect of NB-DNJ affected dramatically
the folding pathway of the nascent chain. This proved to be strictly
controlled by the interaction with calnexin (29-31). Our more recent
studies demonstrated that under the same inhibitory conditions in the
same cell line, the TRP-1 polypeptide chain was able to overcome the
glucosidase blockade by the action of the Golgi endomannosidase, which
allowed the further processing of the N-glycans to complex
structures (32). These findings prompted us to hypothesize that in the
presence of the ER glucosidase inhibitors TRP-1 chain could fold by
alternative pathways to a different conformation that could also
influence the further processing of its N-glycans (for a
review see Ref. 33).
In this paper, we investigated the folding pathway of TRP-1 synthesized
in mouse melanoma cells. We demonstrate that disulfide bonds
post-translationally formed are essential for TRP-1 maturation and
stability. The nascent chain is retained in the ER until the attainment
of a conformation with a disulfide bond pattern conferring DTT
resistance. During folding, TRP-1 interacts with calnexin, and this
interaction is prolonged when the S S bonds are prevented from
forming. The inhibition of N-glycan processing in the ER perturbs but does not completely prevent TRP-1 folding and maturation and does not affect its stability. In NB-DNJ-treated cells TRP-1 polypeptide, which does not bind to calnexin but binds to BiP, acquires
a conformation stabilized also by disulfides.
 |
MATERIALS AND METHODS |
Reagents, Antibodies, and Enzymes--
NB-DNJ was a gift from
Searle Monsanto (St. Louis, MO). N-Ethylmaleimide (NEM),
dithiothreitol (DTT), HEPES, CHAPS, L-methionine, and
apyrase were from Sigma. Protein A-Sepharose was from Amersham Pharmacia Biotech and protease mixture inhibitor
(CompleteTM) from Roche Molecular Biochemicals. The rabbit
anti-TRP-1 antiserum ( PEP1) was a gift from Dr. V. J. Hearing
(National Institutes of Health, Bethesda). Anti-calnexin antibodies
were a gift from Dr. J. J. M. Bergeron (Mc Gill University,
Montreal, Canada), and anti-BiP antibodies were kindly provided by Dr.
L. M. Hendershot (St. Jude Children's Research Hospital, Memphis,
TN). [35S]Methionine/cysteine (Tran35S-label
1100 Ci/mmol) was from ICN Flow (Thame, Oxfordshire, UK). Endoglycosidase H (Endo H) and peptide-N-glycosidase F
(PNGaseF) were from New England Biolabs (Beverly, MA). All other
chemicals were from Sigma.
Cell Culture--
B16 F1 mouse melanoma cells (European
Collection of Animal Cell Cultures, Porton Down, UK) were cultured in
RPMI 1640 medium (Life Technologies, Inc.) containing 10% (v/v) fetal
calf serum (Sigma), 50 units/ml penicillin, and 50 mg/ml streptomycin
(Life Technologies, Inc.). The cells were maintained at 37 °C in an atmosphere of air/CO2 (19:1).
Pulse-Chase Experiments--
B16 mouse melanoma cells were
harvested with EDTA washed three times with 0.1 M
phosphate-buffered saline, pH 7.2, and resuspended in methionine- and
cysteine-free RPMI 1640 medium (Life Technologies, Inc.). Cells
(107 cells/ml) were preincubated for 1 h at 37 °C
before the addition of
[35S]methionine/[35S]cysteine at 200 µCi/ml. Following the labeling period of 10 min, RPMI medium
containing 5 mM unlabeled methionine was added. 5 mM DTT was added to the cells 5 min before the pulse and
maintained at the same concentration during the chase periods. In
NB-DNJ experiments cells were cultured before labeling for 2 h in
normal medium containing 5 mM NB-DNJ, and the inhibitor was
further maintained at the same concentration during the chase periods.
At the indicated times, the chase media were removed, and the cells
were harvested by scrapping into ice-cold phosphate-buffered saline.
Samples analyzed for the S S bond formation were incubated before
lysis for 1 h at 4 °C with 20 mM NEM to block the
free SH groups and to prevent the nonspecific formation of S S bonds.
Cells were lysed in 0.5 ml of lysis buffer (50 mM HEPES, pH
7.5, containing 2% (w/v) CHAPS, 200 mM NaCl, and
proteinase inhibitors), for 1 h on ice. When samples were to be
used for immunoprecipitation of BiP, cells were lysed in the presence
of 20 units/ml apyrase (to enzymatically deplete ATP).
Immunoprecipitation and SDS-PAGE--
35S-Labeled
cell lysates were precleared with 20 µl of protein A-Sepharose for
2 h at 4 °C and incubated with PEP1, anti-calnexin, or
anti-BiP antisera for 2 h at 4 °C. The immunocomplexes were separated by incubation with 20 µl of protein A-Sepharose for 2 h at 4 °C. The slurry was washed with 50 mM HEPES, pH
7.5, containing 0.5% CHAPS and 200 mM NaCl. TRP-1 was
further eluted in 1% SDS for 1 h at room temperature divided in
three and (a) mixed before running with SDS-PAGE sample
buffer without -mercaptoethanol (non-denaturing and non-reducing
conditions), (b) incubated for 5 min at 100 °C and mixed
with SDS-PAGE sample buffer without -mercaptoethanol (denaturing and
non-reducing conditions), (c) incubated in SDS-PAGE sample
buffer with -mercaptoethanol for 5 min at 100 °C (denaturing and
reducing conditions). When TRP-1 bound to calnexin or BiP was analyzed,
samples were eluted for 1 h at room temperature in lysis buffer
containing 1% SDS. SDS concentration was decreased in eluates at
0.1%, and TRP-1 was immunoprecipitated with PEP1. Unless other
specifications were made, samples were run in SDS-7.5% PAGE and
analyzed by autoradiography.
Endo H and PNGaseF Digestion--
35S-Labeled
samples were digested with Endo H or PNGaseF as described (14).
Briefly, TRP-1 samples were eluted from the protein A-Sepharose
in Endo H or PNGaseF denaturing buffer, by incubation for 5 min at
100 °C. The eluted amount was digested in the reaction buffer of
either Endo H or PNGaseF with 500 units of Endo H or PNGase F for
18 h at 37 °C, run in SDS-PAGE, and analyzed by autoradiography.
 |
RESULTS |
TRP-1 Folding in B16 Mouse Melanoma Cells--
We monitored TRP-1
folding in pulse-labeled B16 cells by immunoprecipitation of cell
lysates at different chase time points with PEP1 antiserum (34) and
analysis of TRP-1 by non-reducing SDS-PAGE. In non-reducing SDS-PAGE, a
protein in an open or reduced conformation migrates slower than its
compact or oxidized form. As shown in Fig.
1A, the slower migrating bands
observed at 0 and 15 min of chase (lanes 1 and 2)
are replaced by a faster migrating band at 30 min (lane 3).
This indicates that the TRP-1 chain collapses to a compact form in 30 min after synthesis. No further increase in mobility at 45, 60, or 120 min of chase was detected (lanes 4-6) showing that
further processing to complex type N-glycans has no effect
on the migration of TRP-1. A similar behavior was observed for
tyrosinase in non-reducing gels (29). Our interpretation is that in
non-reducing gels, the migration velocity of TRP-1 is dominated by the
form rather than by the molecular weight, which in turn is prevailing
in reducing gels. To characterize the folding kinetics of the TRP-1
chain, the above samples were analyzed in SDS-PAGE under (a)
non-denaturing and non-reducing conditions, (b) denaturing
and non-reducing conditions, and (c) denaturing and reducing
conditions (see "Materials and Methods"). As can be observed in
Fig. 1B a faster migration was detected for the
non-denatured (a) versus denatured (b)
samples at 15, 30, and 45 min (lanes 4 and 5, 7 and 8, and 10 and 11). However, no
differences in the TRP-1 sample migration at 0 min of chase before and
after thermal denaturation can be detected (lanes 1 and
2). This indicates that some secondary structures are
gradually formed in TRP-1 during folding. Moreover, the reduced forms
of TRP-1 (c) migrate significantly higher than the
non-reduced denatured ones (b) at all chase points, and this
proves that TRP-1 carries disulfides.

View larger version (50K):
[in this window]
[in a new window]
|
Fig. 1.
TRP-1 folding in B16 mouse melanoma
cells. A, B16 cells were pulsed for 10 min with
35S and chased for the indicated periods. Cell lysates were
immunoprecipitated with PEP1 antiserum, and the eluted samples were
run in 10% SDS-PAGE under non-reducing conditions. B, each
sample at 0, 15, 30, and 45 min of chase was run in 7.5% SDS-PAGE in
non-denaturing and non-reducing conditions (a), denaturing
and non-reducing conditions (b), denaturing and reducing
conditions (c) as described under "Materials and
Methods" (B). All samples were visualized by
autoradiography.
|
|
Disulfide Bond Formation during TRP-1 Folding--
To determine
whether the S S bonds are involved in TRP-1 folding, we analyzed the
folding process in the presence of the reducing agent DTT. This agent
can quickly penetrate across the cell membrane and prevents the
formation of disulfides in nascent proteins (20, 35). Cells were
incubated 5 min before pulse, pulse-labeled, and chased in the presence
of 5 mM DTT. Before lysis, the cells were incubated for
1 h with 20 mM NEM to block the free SH groups and to
prevent the nonspecific formation of S S bonds. TRP-1 was immunoprecipitated from untreated and DTT-treated cell lysates, and
samples were analyzed in non-reducing conditions in SDS-PAGE (Fig.
2). In all DTT-treated samples, TRP-1
migrates as a band with constant mobility representing TRP-1 in its
fully reduced conformation (lanes 2, 4, 6, and
8). In the absence of DTT, TRP-1 at 0 min chase (lane
1) is already in a partially folded conformation demonstrated by
its slightly increased mobility, when compared with the TRP-1
DTT-treated (lane 2). The difference between the DTT-treated
and untreated samples at 15 min chase (lanes 3 and 4) is even more pronounced indicating that TRP-1 chain
becomes more compact within this period. It can be estimated that 30 min post-pulse TRP-1 has attained the fully oxidized conformation, as
the difference in the electrophoretic mobility between DTT-treated and
untreated samples at 30 and 45 min chase is identical (lanes 5 and 6 and 7 and 8). Since in
the presence of DTT, the appearance of the fully oxidized chain is
prevented, it can be assumed that the two folding intermediates
observed at 0 and 30 min (Fig. 1A, lanes 1 and
3 and Fig. 2, lanes 1 and 5) are
different disulfide intermediates.

View larger version (37K):
[in this window]
[in a new window]
|
Fig. 2.
Kinetics of S S bond formation in TRP-1 in
B16 mouse melanoma cells. B16 cells were pulsed for 10 min with
35S and chased for the indicated periods. In DTT-treated
cells, the reducing agent was added 5 min before pulse in a
concentration of 5 mM, and the cells were chased in the
continuous presence of the reducing agent. Cells were incubated before
lysis with 20 mM NEM, and TRP-1 from both untreated ( )
and DTT-treated (+) cells was immunoprecipitated with PEP1
antiserum, and samples were analyzed in non-denaturing and non-reducing
SDS-PAGE (see "Materials and Methods") and visualized by
autoradiography.
|
|
To discriminate between the different folding stages of TRP-1, an
experiment was designed to block the formation of disulfide bridges at
various stages during TRP-1 folding followed by the monitoring of the
maturation pathway of the intermediates of folding (Fig.
3). Cells were pulse-labeled for 10 min
and chased for 0, 15, 30, and 45 min in normal medium before the
addition of DTT to each sample. The chase was continued for another 45 min in the presence of the reducing agent; hence, the total chase time in this experiment was 45, 60, 75, and 90 min, respectively. At the end
of the chase time cell lysates were immunoprecipitated with PEP1
antiserum and analyzed in reducing SDS-PAGE to monitor the maturation
of the folding intermediates (lanes 1-4). In a control
experiment TRP-1 maturation in untreated cells, at 0, 15, 45, and 60 min of chase, was analyzed (lanes 5-8). TRP-1
immunoprecipitated from cells where DTT was added immediately after
pulse or after 15 min and chased for 45 min migrates as a partially
glycosylated precursor of approximately 69 kDa (lanes 1 and
2). In contrast, the control from untreated cells migrates
as a band of approximately 69 kDa at 0 and 15 min of chase (lanes
5 and 6) and as a 75-kDa form at 45 and 60 min of chase
(lanes 7 and 8). The 75-kDa form of TRP-1 can be
visualized in the samples in which DTT was added after 30 or 45 min
chase and maintained for 45 min (lanes 3 and 4).
These results indicate that within approximately 30 min in the absence
of the reducing agent TRP-1 attained a native conformation stabilized
by the formation of S S bonds, which is not affected by the presence
of DTT in the culture medium.

View larger version (37K):
[in this window]
[in a new window]
|
Fig. 3.
DTT resistance of the TRP-1 folding
chain. B16 cells were labeled for 10 min with 35S and
chased for 0, 15, 30, and 45 min in the absence of DTT and for
additional 45 min in the presence of DTT (lanes 1-4) or in
the total absence of the reducing agent (lanes
5-8). To detect the increase of the molecular weight
of TRP-1, intermediates samples were run in reducing SDS-PAGE and
visualized by autoradiography.
|
|
TRP-1 Maturation and Transport Depend on the Formation of S S
Bonds--
To investigate the role of disulfides in TRP-1 maturation,
the samples from the previous pulse-chase experiment (presented in Fig.
2) were analyzed under reducing conditions (Fig.
4A). TRP-1 chain from
untreated cells migrates at 69 kDa for the first 15 min (lanes
1 and 3) showing an increase in molecular mass
to 75 kDa at 45 min of chase (lane 5). In DTT-treated cells,
TRP-1 migrated as a 69-kDa precursor for all chase times analyzed
(lanes 2, 4, and 6) suggesting that no maturation
occurred in the presence of DTT. Our previous studies have shown that
within 1 h of chase TRP-1 acquires complex oligosaccharides
becoming partially resistant to Endo H digestion (14). Indeed, after
Endo H treatment, which completely removes high mannose and hybrid
oligosaccharides attached to the polypeptide, TRP-1 from DTT-treated
sample at 1 h of chase co-migrated with untreated TRP-1 at 0 min
of chase (Fig. 4A, lanes 7 and 8).
These results indicate that the glycans attached on TRP-1 synthesized
in the continuous presence of DTT were not further processed to complex
structures.

View larger version (35K):
[in this window]
[in a new window]
|
Fig. 4.
TRP-1 transport, maturation, and degradation
depend on the disulfide bonds formation. A, B16 cells
were labeled for 10 min with 35S and chased in the absence
( ) and presence (+) of 5 mM DTT for the indicated
periods. TRP-1 was immunoprecipitated from cell lysates with PEP1
antiserum, and samples were run in reducing SDS-PAGE (lanes
1-6). To observe the maturation of complex
oligosaccharides, TRP-1 from untreated cells at 0 min of chase
(lane 7) was compared with TRP-1 at 60 min of chase from
DTT-treated cells digested with Endo H (lane 8). Samples
were visualized by autoradiography. B, cells were labeled
for 10 min with 35S and chased in the presence of 5 mM DTT up to 4 h, analyzed in reducing SDS-PAGE, and
visualized by autoradiography.
|
|
To monitor the degradation process of TRP-1 synthesized in the presence
of DTT, TRP-1 samples immunoprecipitated from B16 cells pulse-chased
for the time points shown in Fig. 4B were analyzed by
SDS-PAGE under reducing conditions. There was a significant decrease in
the intensity of the TRP-1 band from 0 to 1 h of chase (lanes 1 and 2) followed by a gradual
disappearance of the band. In contrast, TRP-1 in the untreated cells
was shown to have a half-life longer than 5 h (data not shown)
indicating that TRP-1 degradation is accelerated when the glycoprotein
is synthesized in the continuous presence of DTT.
TRP-1 Folding in the Presence of ER Glucosidase
Inhibitors--
TRP-1 is a glycoprotein with 6 potential
N-glycosylation sites. To determine whether
N-glycosylation has a role in TRP-1 folding, we monitored
TRP-1 folding in the presence of N-butyl-deoxynojirimicin (NB-DNJ). NB-DNJ is an inhibitor of -glucosidases I and II, which prevents N-glycan trimming in ER compartment and calnexin
binding to the monoglucosylated protein precursors (28). Two hours
before pulse the inhibitor was added to the culture medium to a
concentration of 5 mM and maintained during the pulse-chase
process. The cells were pulsed for 10 min with
[35S]methionine and chased for 0, 15, and 60 min. TRP-1
immunoprecipitated from the cell lysates was analyzed in SDS-PAGE under
(a) non-denaturing and non-reducing conditions,
(b) denaturing and non-reducing conditions, and
(c) denaturing and reducing conditions as described under "Materials and Methods." As shown in Fig.
5A the native (a)
and denatured non-reduced (b) samples co-migrate in SDS-PAGE
for all chase time points. Unlike TRP-1 normally processed, TRP-1 from NB-DNJ-treated cells does not change its conformation after thermal denaturation. The reduced form of TRP-1 (c) from
NB-DNJ-treated cells migrated in a slightly higher position than the
non-reduced forms, and this served as a proof for the presence of
disulfide bonds. It could be concluded that the TRP-1 polypeptide chain was able to fold into an oxidized form despite the presence of the
N-glycosylation inhibitor in the culture medium.

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 5.
TRP-1 folding in B16 melanoma cells cultured
in the presence of NB-DNJ. A, 5 mM NB-DNJ
was added to the B16 cells 2 h before pulse. Cells were labeled
for 10 min with 35S and chased for the indicated periods in
the presence of the same concentration of the inhibitor. Cell lysates
were immunoprecipitated with PEP1 antiserum, and the eluted samples
were run in non-denaturing and non-reducing conditions (a),
denaturing and non-reducing conditions (b), and denaturing
and reducing conditions (c) (see "Materials and
Methods"). B, cells were cultured for 2 h before
pulse in the presence of 5 mM NB-DNJ, labeled for 10 min
with 35S, and chased for 0, 15, 30, 45, and 60 min in the
presence of NB-DNJ. 5 mM DTT was added to the first four
samples, and the chase was continued for another 45 min in the
presence of both NB-DNJ and DTT. Cell lysates were
immunoprecipitated with PEP1 antiserum and digested with Endo H
(lanes 1-4) or with PNGaseF (lane 5). All
samples were visualized after running in reducing SDS-PAGE by
autoradiography.
|
|
Since the folding rate of tyrosinase is considerably accelerated in the
presence of NB-DNJ (29), it was of interest to determine the kinetics
of folding to a stable conformation of the TRP-1 chain under similar
conditions. Cells were incubated for 2 h in the presence of 5 mM NB-DNJ, pulsed for 10 min, and chased in the presence of
the inhibitor for 0, 15, 30, and 45 min. After chase, 5 mM
DTT was added to each sample, and the chase was continued in the
presence of both NB-DNJ and DTT. For better evidence of the TRP
maturation along the indicated chase points, samples were digested with
Endo H (Fig. 5B, lanes 1-4). A sample of mature TRP-1, synthesized in the presence of NB-DNJ only, was completely deglycosylated with PNGase F thus indicating the position of the TRP-1
polypeptide (lane 5). The results of this experiment show that when TRP-1 is synthesized in the presence of NB-DNJ up to 15 min
post-pulse and another 45 min with both NB-DNJ and DTT, the protein
remained totally sensitive to Endo H (lanes 1 and 2). When DTT is added after 30 and 45 min and maintained for
another 45 min, TRP-1 synthesized in the presence of the inhibitor
becomes more resistant to Endo H and acquires oligosaccharides of
complex structure (lanes 3 and 4). The Endo H
digestion pattern of the last two chase points is similar with the
pattern of mature NB-DNJ TRP-1 reported previously (14). The results
indicate that TRP-1 synthesized in the presence of NB-DNJ acquires the
competent transport conformation, being resistant to further DTT
exposure, within approximately the same time as TRP-1 from untreated cells.
TRP-1 Interaction with ER Resident Chaperones--
By having
established that inhibition of glucose trimming influences TRP-1
folding, investigations were performed to determine the role of the
chaperone calnexin in TRP-1 folding. B16 cells were pulse-labeled for
10 min with [35S]methionine and chased for 0, 15, 30, 45, and 60 min. Cells were lysed in HEPES/CHAPS buffer that preserves the
interactions of calnexin with substrate proteins (36) and
immunoprecipitated sequentially with anti-calnexin antiserum followed
by PEP1 antiserum. The results presented in Fig. 6 (lanes
1-5) showed that TRP-1 bound to calnexin was detected immediately
after pulse, and the amount of TRP-1 bound to calnexin decreased
progressively after 15 and 30 min of chase. After approximately 45 min
of chase no interaction with calnexin was detected. This was expected
since, as we previously reported, at 45 min of chase TRP-1 appeared as a fully glycosylated protein that has already passed the ER compartment (14). It can be observed that time course of TRP-1 associated with
calnexin is well correlated with the formation of the fully oxidized
chain in approximately 30 min post-pulse. Next, we investigated the
interaction of TRP-1 with calnexin under conditions where S S bonds in
TRP-1 are prevented from forming. The cells were incubated 5 min before
pulse with 5 mM DTT, pulse-labeled for 10 min, chased for
45 min and 1 and 3 h in the presence of 5 mM DTT, and
TRP-1 was retrieved by double immunoprecipitation (Fig. 6, lanes 6-8). Compared with
the untreated cells when after 30 min we could not detect any
interaction with calnexin (Fig. 6, lanes 4 and
5), in DTT-treated cells TRP-1 is bound to calnexin for up
to 1 h of chase (lane 6).

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 6.
Interaction of TRP-1 with calnexin is
prolonged in DTT-treated cells. B16 cells were pulsed for 10 min
with 35S and chased in the absence of DTT ( ) up to 60 min
(lanes 1-5) or in the presence of 5 mM DTT (+)
for 180 min (lanes 6-8). TRP-1 bound to calnexin was
retrieved by double immunoprecipitation with anti-calnexin and PEP1
antisera and run in reducing SDS-PAGE. Samples were visualized by
autoradiography.
|
|
Although we did not detect any interaction with calnexin in
NB-DNJ-treated cells (data not shown), we hypothesized that another chaperone could assist TRP-1 during folding to acquire its stable conformation. Analysis of TRP-1 association with the ER-resident chaperone BiP was performed in B16 cells pulsed 10 min and analyzed for
5, 10, and 45 min (Fig. 7) in the
presence or absence of NB-DNJ and DTT. Cells were lysed and
immunoprecipitated with anti-BiP antiserum (37) followed by PEP1
antiserum and analyzed in reducing SDS-PAGE. We observed that
significantly more TRP-1 is co-immunoprecipitated by BiP in
NB-DNJ-treated cells than in the untreated controls for the same chase
period (lanes 1-3 and 4-6). TRP-1 also binds to
BiP up to 45 min chase (lanes 7-9) in DTT-treated cells, in the absence of disulfides. The amount of TRP-1 bound to BiP slightly decreased within 10 min of chase in NB-DNJ-treated cells (lanes 4-6), and no interaction was detected at 30 min of chase (data not shown).

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 7.
TRP-1 interaction with BiP in NB-DNJ- and
DTT-treated cells. B16 cells were pulsed for 10 min with
35S and chased in the absence ( ) and presence (+) of 5 mM NB-DNJ for 0, 5, and 10 min or in the presence of 5 mM DTT (+) for 0, 10, and 45 min. TRP-1 bound to BiP was
retrieved by double immunoprecipitation with anti-BiP and PEP1
antisera, run in reducing SDS-PAGE, and detected by
autoradiography.
|
|
 |
DISCUSSION |
TRP-1 is a melanosomal membrane glycoprotein that is synthesized
in the ER, transits the Golgi apparatus, and accumulates in the
trans-Golgi network before being targeted to the melanosome. We have
recently shown that in B16 mouse melanoma cells TRP-1 is synthesized as
a precursor polypeptide of 69 kDa acquiring the first complex
oligosaccharide structures in the Golgi in approximately 30 min of
chase (14). Within approximately 45 min of chase the TRP-1 polypeptide
chain is completely processed to a 75-kDa mature glycoprotein (14). A
similar time course of maturation has been reported for TRP-1
synthesized in human melanoma cells (5) documenting the same ER
residence time for this glycoprotein in two different melanoma cells
in vivo.
In this study, we have investigated the ER-associated events
accompanying the folding of the nascent TRP-1 polypeptide chain required for further trafficking through the secretory pathway. We show
here that TRP-1 synthesized in mouse melanoma cells folds into the most
compacted conformation in the ER in less than 30 min post-pulse. The
final three-dimensional conformation appears to be stabilized not only
by native disulfide bridges but also by non-covalent interactions
sensitive to thermal denaturation, as shown by the SDS-PAGE analysis of
the pulse-chase immunoprecipitates. During the folding process, which
is completed post-translationally, two folding intermediates with
different electrophoretic mobilities in non-reducing gels have been
detected. They differ in their disulfide bonding patterns as shown by
the pulse-chase experiments performed in the presence of the reducing
agent DTT.
The time course formation of stable intermediates during the TRP-1
folding process was monitored by a post-pulse DTT treatment experiment.
This approach allowed the proper folding of the chain before the DTT
exposure occurred but prevented any further disulfide bond formation,
thus facilitating the identification of stable DTT-resistant
conformers. We observed that TRP-1 polypeptide chain does not fold
immediately after synthesis in a stable conformation. This is gradually
completed by 30 min of post-pulse, a time point coinciding with the
appearance of the most oxidized TRP-1 intermediate, followed by its
export from the ER. Although the co-translational formation of some
disulfides cannot be ruled out, our data support the notion that native
disulfides are gradually formed post- translationally, being required
for the completion of the oxidative folding process.
The importance of post-translational disulfide bonds in the maintenance
of the native conformation is different from one protein to another. In
hemagglutinin-neuraminidase protein from Newcastle disease virus, the
protein forced to form all disulfides post-translationally has no
biological activity (38). The folding pathway and the final
conformation of the protein were altered, despite the collapse of the
chain to a compact conformation stabilized by disulfide bridges.
Similarly, the -subunit precursors of the human chorionic gonadotropin, despite incorrect folding (39), could collapse to a
conformation competent for dimerization with the -subunit in
presence of DTT (40). On the contrary, disulfide bond formation in the
acetylcholine receptor occurs post-translationally, preceding the chain
conformational maturation and subunit assembly (41). Our pulse-chase
experiments in the continuous presence of DTT followed by the
immunoprecipitation of TRP-1 showed that disulfide bond formation is
crucial for the transport, maturation, and degradation processes of the
nascent chain. By blocking the S S bonds formation, the reducing agent
also prevented TRP-1 oxidative folding affecting the protein maturation
process. As a consequence, TRP-1-synthesized in the continuous presence
of DTT does not reach the trans-Golgi compartment and therefore does
not acquire complex oligosaccharides being targeted to degradation much
faster than the normally processed chain. It is very likely that TRP-1
in its fully reduced conformation cannot escape the ER quality control
system and is probably eliminated by a common mechanism adopted for
other severely misfolded proteins (42). Knowing that besides TRP-1, all
the other members of the TRP family contain 15 cysteine residues in
well conserved positions along the polypeptide chain, one could
consider the role of disulfide bridges for the biological function of
TRPs (1, 12, 13). However, there is no clear information at this time
on the number and location of the S S bonds on these chains.
Interestingly, two classic mutations, in tyrosinase (albino)
and in TRP-1 (brown), are substitutions of Cys-5 and Cys-4,
respectively, both localized within the epidermal growth factor domain,
with a well characterized pattern of the S S bonds in many proteins
(43). A more recently characterized human albinism mutation is the
substitution of Cys-2 with Arg in tyrosinase (44). Although the
mechanism of tyrosinase and TRP-1 inactivation in these genetic
disorders is not well characterized, it is believed that
tyrosinase-negative albinism is an ER retention disease (45, 46). As
the ER retention is a process associated with the misfolding and
degradation of the nascent chain, these observations together with our
data could imply that critical cysteine residues may be involved in
designing the native conformation of TRP polypeptide chain. Further
studies are needed for a better understanding of the role of particular cysteines in the formation of the correctly folded conformation of TRP glycoproteins.
The structural homology between TRP-1 and tyrosinase is not restricted
only to the position of the cysteine residues, as it has been already
mentioned. Another important similarity in their structure is the
presence of six potential glycosylation sites on the polypeptide chain
(1, 12, 13). In the case of tyrosinase we have previously shown that
correct folding of the chain is highly dependent on the association of
the folding polypeptide with the ER resident chaperones
calnexin/calreticulin (29). Moreover, the kinetics of the folding
pathway is changed when the interaction with calnexin/calreticulin is
prevented. In the presence of the -glucosidases inhibitor NB-DNJ,
the tyrosinase chain folds "faster" to an inactive state (29).
Surprisingly, the data presented here show that TRP-1 synthesized in
B16 melanoma cells treated with NB-DNJ folds with similar kinetics as
under normal conditions. In the presence of this drug, TRP-1
polypeptide is able to fold to an oxidized form stabilized by disulfide
bridges, as shown by the electrophoretic pattern of the chain in
reducing versus non-reducing conditions. Moreover, the
post-pulse DTT experiment revealed that in the presence of NB-DNJ a
stable conformation preserved by S S bonds is acquired within 30 min
post-pulse as is observed in the normally processed protein. However,
the conformation of this chain is different from the conformation of
normal TRP-1 as suggested by the different behavior toward thermal
denaturation. These results confirm previously reported data showing
that NB-DNJ treated TRP-1 had a different conformation (32) and
acquired less complex oligosaccharides (14) as compared with the
normally processed protein.
The co-immunoprecipitation experiments with anti-calnexin and PEP1
antiserum showed that TRP-1 associates with calnexin for the first 30 min of synthesis until the chain acquires its native conformation.
Under conditions that maintain the polypeptide in a reduced but
glucosylated state, such as in DTT treatment, TRP-1 shows a prolonged
interaction with calnexin before being targeted to degradation. In
contrast to TRP-1 synthesized in normal conditions, NB-DNJ-treated
TRP-1 does not interact with calnexin but with BiP. In NB-DNJ-treated
cells, TRP-1 binds avidly to BiP, whereas in normally processed TRP-1
this interaction is hardly detected. It is known that BiP binds to the
hydrophobic patches that are transiently exposed mainly during the
early steps of polypeptide folding, and this was confirmed by the
prolonged interaction of BiP with TRP-1 in DTT-treated cells. The poor
interaction of TRP-1 with BiP in the untreated cells indicates that
TRP-1 hydrophobic patches are rapidly folded into a conformation with
very little accessibility to BiP. In contrast, interaction with BiP is
dramatically increased in the absence of calnexin and prolonged in the
presence of denaturing agents. Interestingly, dissociation of the chain from BiP coincides with the appearance of the oxidized form of NB-DNJ-treated TRP-1 and with the targeting for degradation moment of
TRP-1 synthesized in the presence of DTT. Collectively, these results
indicate that in the folding process of TRP-1, BiP is used in the
absence of the lectin chaperone calnexin and that under severe stress
BiP and calnexin act simultaneously to help the polypeptide chain
folding. Further confirmation comes from previously reported
experiments showing that BiP associates especially well with early
folding intermediates and can serve as a backup for calnexin or
calreticulin in retaining partially folded structures (47, 48).
In conclusion, the maturation and stability of TRP-1 polypeptide chain
are differently affected by perturbation of the folding process. Under
normal conditions in vivo, the TRP-1 chain adopts a
conformation stabilized by intramolecular S S bonds and non-covalent interactions. As in the case of the highly homologous tyrosinase, TRP-1
folding is completed post-translationally. In contrast to tyrosinase,
the time course of TRP-1 folding in melanoma cells is 6-fold faster. We
were able to demonstrate that the time spent by TRP-1 in the ER is
required for the attainment of the stable compact conformation
resistant to DTT attack. Similar to tyrosinase, the TRP-1 nascent chain
folding is mediated by calnexin. In case of inhibition of
N-glycan processing in the ER, the interaction with calnexin
is prevented. In contrast to NB-DNJ-treated tyrosinase that folds
faster than the wild type, NB-DNJ-treated TRP-1 assisted by BiP is able
to fold with similar kinetics as the untreated TRP-1 and acquire the
DTT-resistant conformation. However, this conformation is different
from the one of wild type, and it may influence the protein processing
in the next compartments of the secretory pathway (14). When the
protein is forced to adopt a fully reduced conformation, its folding
and maturation are prevented, the polypeptide chain being retained in
the ER by prolonged association with the chaperones calnexin and BiP,
prior of being targeted to degradation.
 |
ACKNOWLEDGEMENTS |
We thank V. Hearing (National Institutes of
Health, Bethesda) for -PEP1 antiserum, J. J. M. Bergeron
(McGill University, Montreal, Canada) for anti-calnexin antibodies, and
Dr. L. M. Hendershot (St. Jude Children's Research Hospital,
Memphis, TN) for anti-BiP antibodies.
 |
FOOTNOTES |
*
This work was supported by grants from the Wellcome Trust,
Collaborative Research Initiative Grant 053441, the Romanian Academy, and the Romanian Ministry of Research and Technology.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: Inst. of
Biochemistry, Splaiul Independentei 296, 77700 Bucharest 17, Romania. Tel.: 401 223 90 69; Fax: 401 223 90 68; E-mail: Stefana.Petrescu@ biochim.ro.
Published, JBC Papers in Press, July 27, 2000, DOI 10.1074/jbc.M005186200
 |
ABBREVIATIONS |
The abbreviations used are:
TRPs, tyrosinase-related proteins;
DTT, dithiothreitol;
ER, endoplasmic
reticulum;
NB-DNJ, N-butyl-deoxynojirimicin;
NEM, N-ethylmaleimide;
CHAPS, 3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate;
PAGE, polyacrylamide gel electrophoresis;
Endo H, endoglycosidase H;
PNGaseF, peptide-N-glycosidase F.
 |
REFERENCES |
| 1.
|
Hearing, V. J.,
and King, R. A.
(1993)
in
Pigmentation and Pigmentary Abnormalities
(Levine, N., ed)
, pp. 3-32, CRC Press, Inc., Boca Raton, FL
|
| 2.
|
Vijayasaradhi, S.,
Bouchard, B.,
and Houghton, A. N.
(1990)
J. Exp. Med.
171,
1375-1380
|
| 3.
|
Houghton, A. N.
(1994)
J. Exp. Med.
180,
1-4
|
| 4.
|
Houghton, A. N.,
Real, F. X.,
Davis, L. J.,
Cordon-Cardo, C.,
and Old, L. J.
(1987)
J. Exp. Med.
165,
812-829
|
| 5.
|
Vijayasaradhi, S.,
Doskoch, P. M.,
and Houghton, A. N.
(1991)
Exp. Cell. Res.
196,
233-240
|
| 6.
|
Der, J. E.,
Dixon, W. T.,
Jimbow, K.,
and Horikoshi, T.
(1993)
Br. J. Cancer Res.
67,
47-57
|
| 7.
|
Jackson, I. J.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
4392-4396
|
| 8.
|
Muller, G.,
Ruppert, S.,
Schmid, E.,
and Schutz, G.
(1988)
EMBO J.
7,
2723-2730
|
| 9.
|
Zdarsky, E.,
Favor, J.,
and Jackson, I. J.
(1990)
Genetics
126,
443-449
|
| 10.
|
Orlow, S. J.,
Zhou, B.-K.,
Chakraborty, A. K.,
Drucker, M.,
Pifko-Hirst, S.,
and Pawelek, J. M.
(1994)
J. Invest. Dermatol.
10,
196-201
|
| 11.
|
Kobayashi, T.,
Imokawa, G.,
Bennett, D. C.,
and Hearing, V. J.
(1998)
J. Biol. Chem.
273,
31801-31805
|
| 12.
|
Spritz, R. A.,
and Hearing, V. J.
(1994)
in
Advances in Human Genetics
(Hirschhorn, K.
, and Harris, H., eds)
, pp. 1-45, Plenum Publishing Corp., New York
|
| 13.
|
King, R. A.,
Oetting, W. S.,
and Hearing, V. J.
(1995)
in
Metabolic and Molecular Bases of Inherited Disease
(Scriver, C. R.
, Beaudet, A. L.
, Sly, W. S.
, and Valle, D., eds)
, pp. 4353-4392, McGraw-Hill Inc., New York
|
| 14.
|
Negroiu, G.,
Branza-Nichita, N.,
Petrescu, A. J.,
Dwek, R. A.,
and Petrescu, S. M.
(1999)
Biochem. J.
344,
659-665
|
| 15.
|
Freedman, R. B.
(1989)
Cell
57,
1069-1072
|
| 16.
|
Freedman, R. B.,
Hirst, T. R.,
and Tuite, M. F.
(1994)
Trends Biochem. Sci.
19,
331-336
|
| 17.
|
Gunther, R.,
Srinivasan, M.,
Haugejorden, S.,
Green, M.,
Ehbrecht, I. M.,
and Kuntzel, H.
(1993)
J. Biol. Chem.
268,
7728-7732
|
| 18.
|
Alberini, C. M.,
Bet, P.,
Milstein, C.,
and Sitia, R.
(1990)
Nature
347,
485-487
|
| 19.
|
Braakman, I.,
Hoover-Litty, H.,
Wagner, K. R.,
and Helenius, A.
(1991)
J. Cell Biol.
114,
401-411
|
| 20.
|
Braakman, I.,
Helenius, J.,
and Helenius, A
(1992)
EMBO J.
11,
1717-1722
|
| 21.
|
Lodish, H. F.,
and Kong, N.
(1993)
J. Biol. Chem.
268,
20598-20605
|
| 22.
|
Losch, A.,
and Koch-Brandt, C.
(1995)
J. Biol. Chem.
270,
11543-11548
|
| 23.
|
Trombetta, E. S.,
and Helenius, A.
(1998)
Curr. Opin. Struct. Biol.
8,
587-592
|
| 24.
|
Hebert, D. N.,
Foellmer, B.,
and Helenius, A.
(1995)
Cell
81,
425-433
|
| 25.
|
Leitzgen, K.,
and Haas, I. G.
(1998)
Chemtracts-Biochem. Mol. Biol.
11,
423-445
|
| 26.
|
Skowronek, N. H.,
Hendershot, L. M.,
and Haas, I. G.
(1998)
Cell
92,
747-758
|
| 27.
|
Molinari, M.,
and Helenius, A.
(2000)
Science
288,
331-333
|
| 28.
|
Petrescu, S. M.,
Petrescu, A. J.,
Titu, H. N.,
Dwek, R. A.,
and Platt, F. M.
(1997)
J. Biol. Chem.
272,
15796-15803
|
| 29.
|
Branza-Nichita, N.,
Petrescu, A. J.,
Dwek, R. A.,
Wormald, M. R.,
Platt, F. M.,
and Petrescu, S. M.
(1999)
Biochem. Biophys. Res. Commun.
261,
720-725
|
| 30.
|
Branza-Nichita, N.,
Negroiu, G.,
Petrescu, A. J.,
Garman, E. F.,
Platt, F. M.,
Wormald, M. R.,
Dwek, R. A.,
and Petrescu, S. M.
(2000)
J. Biol. Chem.
275,
8169-8175
|
| 31.
|
Toyofuku, K.,
Wada, I.,
Hirosaki, K.,
Park, J. S.,
Hori, Y.,
and Jimbow, K.
(1999)
J. Biochem. (Tokyo)
125,
82-89
|
| 32.
|
Negroiu, G.,
Branza-Nichita, N.,
Costin, G. E.,
Titu, H.,
Petrescu, A. J.,
Dwek, R. A.,
and Petrescu, S. M.
(1999)
Cell. Mol. Biol.
45,
1001-1010
|
| 33.
|
Petrescu, S. M.,
Branza-Nichita, N.,
Negroiu, G.,
Petrescu, A. J.,
and Dwek, R. A.
(2000)
Biochemistry
39,
5229-5237
|
| 34.
|
Aroca, P.,
Urabe, K.,
Kobayashi, T.,
Tsukamoto, K.,
and Hearing, V. J.
(1993)
J. Biol. Chem.
268,
25650-25655
|
| 35.
|
Tatu, U.,
Braakman, I.,
and Helenius, A.
(1993)
EMBO J.
12,
2151-2157
|
| 36.
|
Hebert, D. N.,
Zhang, J. X.,
Chen, W.,
Foellmer, B.,
and Helenius, A.
(1997)
J. Cell Biol.
139,
613-623
|
| 37.
|
Wey, J.,
and Hendershot, L. M.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
5269-5274
|
| 38.
|
McGinnes, L. W.,
and Morrison, T. G.
(1996)
Virology
224,
465-476
|
| 39.
|
Feng, W.,
Matzuk, M. M.,
Mountjoy, K.,
Bedows, E.,
Ruddon, R. W.,
and Boime, I.
(1995)
J. Biol. Chem.
270,
11851-1159
|
| 40.
|
Singh, V.,
and Merz, W. E.
(2000)
J. Biol. Chem.
275,
11765-11770
|
| 41.
|
Gelman, M. S.,
and Prives, J. M.
(1996)
J. Biol. Chem.
271,
10709-10714
|
| 42.
|
de Silva, A. M.,
Balch, W. E.,
and Helenius, A.
(1990)
J. Cell Biol.
111,
857-866
|
| 43.
|
Davis, C. G.
(1990)
New Biol.
2,
410-419
|
| 44.
|
Spritz, R. A.,
Strunk, K. M.,
Hsieh, C. L.,
Sekhon, G. S.,
and Francke, U.
(1991)
Am. J. Hum. Genet.
48,
318-324
|
| 45.
|
Halaban, R.,
Cheng, E.,
Zhang, Y.,
Moellmann, G.,
Hanlon, D.,
Michalak, M.,
Setaluri, V.,
and Hebert, D. N.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
6210-6215
|
| 46.
|
Halaban, R.,
Svedine, S.,
Cheng, E.,
Smicun, Y.,
Aron, R.,
and Hebert, D. N.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
5889-5894
|
| 47.
|
Muresan, Z.,
and Arvan, P.
(1998)
Mol. Endocrinol.
12,
458-467
|
| 48.
|
Zhang, J. X.,
Braakman, I.,
Matlack, K. E.,
and Helenius, A.
(1997)
Mol. Biol. Cell
8,
1943-1954
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
C. I. Popescu, A. Mares, L. Zdrentu, N. Zitzmann, R. A. Dwek, and S. M. Petrescu
Productive Folding of Tyrosinase Ectodomain Is Controlled by the Transmembrane Anchor
J. Biol. Chem.,
August 4, 2006;
281(31):
21682 - 21689.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. N. Roybal, S. Yang, C.-W. Sun, D. Hurtado, D. L. Vander Jagt, T. M. Townes, and S. F. Abcouwer
Homocysteine Increases the Expression of Vascular Endothelial Growth Factor by a Mechanism Involving Endoplasmic Reticulum Stress and Transcription Factor ATF4
J. Biol. Chem.,
April 9, 2004;
279(15):
14844 - 14852.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Watabe, J. C. Valencia, K.-i. Yasumoto, T. Kushimoto, H. Ando, J. Muller, W. D. Vieira, M. Mizoguchi, E. Appella, and V. J. Hearing
Regulation of Tyrosinase Processing and Trafficking by Organellar pH and by Proteasome Activity
J. Biol. Chem.,
February 27, 2004;
279(9):
7971 - 7981.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Negroiu, R. A. Dwek, and S. M. Petrescu
The Inhibition of Early N-Glycan Processing Targets TRP-2 to Degradation in B16 Melanoma Cells
J. Biol. Chem.,
July 11, 2003;
278(29):
27035 - 27042.
[Abstract]
[Full Text]
[PDF]
| |